Immuneering (IMRX) Change in Cash (2020 - 2026)
Immuneering (IMRX) posted quarterly Change in Cash of -$81.3 million for Q1 2026, down 29045.69% year-over-year from N/an in Q1 2025, and up 17.79% quarter-over-quarter from -$98.9 million in Q4 2025.
Immuneering (IMRX) Change in Cash (2020 - 2026) Analysis & Trends
Immuneering's Change in Cash history runs 7 years deep, the most recent figure standing at -$81.3 million for Q1 2026.
- In Q1 2026, Change in Cash fell 29045.69% year-over-year to -$81.3 million; the TTM figure through Mar 2026 stood at $11.5 million (up 137.66% YoY), while the FY2025 annual figure was $92.5 million, up 497.66% from the prior year.
- Change in Cash for Q1 2026 stood at -$81.3 million, up from -$98.9 million in the prior quarter.
- The five-year high for Change in Cash was $201.2 million in Q3 2025, with the low at -$98.9 million in Q4 2025.
- The 5-year median for Change in Cash is -$6.6 million (2024), against an average of -$1.6 million.
- The sharpest annual moves came in 2025 and 2026: Change in Cash soared 1485.45% in 2025, then sank 29045.69% in 2026.
- Immuneering's Change in Cash stood at -$3.8 million in 2022, then plunged by 128.37% to -$8.6 million in 2023, then fell by 4.94% to -$9.1 million in 2024, then sank by 991.71% to -$98.9 million in 2025, then advanced by 17.79% to -$81.3 million in 2026.
- Business Quant data shows IMRX's Change in Cash at -$81.3 million in Q1 2026, -$98.9 million in Q4 2025, and $201.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 427.25 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.97 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -2.94 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.42 Mn |
| 10 | Immuneering | 327.37 Mn | 327.37 Mn | - | -6.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.00 Mn |
| Mar 31, 2026 | -81.32 Mn |
| Dec 31, 2025 | -98.92 Mn |
| Sep 30, 2025 | 201.21 Mn |
| Jun 30, 2025 | -9.51 Mn |
| Mar 31, 2025 | -279,024.00 |
| Dec 31, 2024 | -9.06 Mn |
| Sep 30, 2024 | -14.52 Mn |
| Jun 30, 2024 | -6.56 Mn |
| Mar 31, 2024 | 6.88 Mn |
| Dec 31, 2023 | -8.63 Mn |
| Sep 30, 2023 | -35.98 Mn |
| Jun 30, 2023 | 26.59 Mn |
| Mar 31, 2023 | 4.79 Mn |
| Dec 31, 2022 | -3.78 Mn |
| Sep 30, 2022 | -11.52 Mn |
| Jun 30, 2022 | 12.73 Mn |
| Mar 31, 2022 | 316,915.00 |
| Dec 31, 2021 | -32.04 Mn |
| Sep 30, 2021 | 56.68 Mn |